NCT04001894View on ClinicalTrials.gov

Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2020

Conditions
Platelet Reactivity
Interventions
DRUG

Ticagrelor 90mg

Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).

DRUG

Clopidogrel 75mg

Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).

Trial Locations (1)

150001

Thrombelastogram, Harbin

All Listed Sponsors
lead

First Affiliated Hospital of Harbin Medical University

OTHER

NCT04001894 - Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease | Biotech Hunter | Biotech Hunter